We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Josh Beckerman
AbbVie Inc. said a clinical trial of its Venclexta (venetoclax) drug in combination with low-dose cytarabine didn't meet its primary endpoint of statistically significant improvement of overall survival for patients with acute myeloid leukemia.
Venclexta is being developed by AbbVie and Roche Holding AG.
AbbVie said results from the VIALE-C trial "are indicative of clinical activity" for the combination. The company said the VIALE-A trial evaluating the drug in combination with azacytidine is ongoing.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 28, 2020 19:50 ET (00:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
